June 21, 2024 09:15 AM EDTUpdated June 23, 10:08 AM

The Endpoints Slack interview: Saji Wickramasekara on where AI misses the mark — and what's next for Benchling

Andrew Dunn

Senior Biopharma Correspondent

As a 22-year-old undergraduate, Saji Wickramasekara followed a well-worn tech world script that remains nearly unheard of in biotech — he dropped out of MIT and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The Endpoints Slack interview: Saji Wickramasekara on where AI misses the mark — and what's next for Benchling

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

Steve Davis leaves Acadia, replaced by Bristol Myers alum; Former J&J exec to lead R&D at Novavax

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

The End­points Slack in­ter­view: Saji Wick­ra­masekara on where AI miss­es the mark — and what's next for Bench­ling

Senior Biopharma Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

The Endpoints Slack interview: Saji Wickramasekara on where AI misses the mark — and what's next for Benchling